Indivior PLC
10710 Midlothian Turnpike
Suite 125
North Chesterfield, VA 23235
United States
804 379 1090
https://www.indivior.com
版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 1,000
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Mark Crossley | CEO & Executive Director | 2.15M | 無 | 無 |
| Mr. Ryan Preblick | CFO & Executive Director | 1.05M | 無 | 無 |
| Dr. Christian Heidbreder | Chief Scientific Officer | 無 | 無 | 無 |
| Mr. Jason Thompson | Vice President of Investor Relations | 無 | 無 | 無 |
| Ms. Cynthia Cetani | Chief Integrity & Compliance Officer | 無 | 無 | 無 |
| Mr. Jeffrey W. Burris | Chief Legal Officer | 無 | 無 | 1972 |
| Mr. Jon Fogle | Chief Human Resources Officer | 無 | 無 | 無 |
| Mr. Richard Simkin | Chief Commercial Officer | 無 | 無 | 無 |
| Mr. Hillel West | Chief Manufacturing & Supply Officer | 無 | 無 | 無 |
| Mr. Vishal Kalia | SVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy Officer | 無 | 無 | 無 |
描述
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
公司管治
截至 2024年5月1日 止，Indivior PLC 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：10；董事會：4；股東權利：1；現金賠償：6。
